Kornimate/medical-research-clean huggingface dataset:
probiotics for weight loss

Conditions: Overweight

Summary: this study will investigate a compound of probiotics and prebiotics in females and males with overweight with the aim to evaluate the effect on weight and metabolic markers. the design is a three month randomized doubled-blinded, three-armed placebo-controlled trial of probiotics for weight loss. normal dose (2 capsules á 0.4g per day) doubled dose (4 capsules á 0.4g per day), or placebo. a second, non-blinded, phase with only the compound of probiotics and prebiotics, with tripple dose (6 capsuled á 0.4g per day), will be performed for individuals who had the compound in the first phase.

participants total number of study participants will be 75-90, consisting of overweight men and women, 18-45 years of age. treatment dietary supplement consisting of probiotic capsules called lb001. it contains strains of pediococcus (bacterial family of lactobacillaceae) and saccharomycetes (kingdom of fungi and the division ascomycota) with a concentration of 13 millions cfu/g. other ingredients (including stabilization) include rice bran, vegetable l-cystein, magnesium salts from vegetable fatty acids. the capsule shell is made of vegetable hydroxypropylmetylcellulosa (hpmc). each capsule has a weight of 0.4 gram. the placebo is made of rice flour. since one of the inclusion criteria is "willingness to lose weight", all study participants, regardless of randomized treatment, will receive general advice regarding healthy lifestyle habits.

Eligibility criteria:
inclusion criteria: * bmi 26.0 - 29,99 kg/m2 * 18-45 years old * willingness to lose weight exclusion criteria: * active weight loss in the last three months * the desire for or planned pregnancy upcoming months * chronic somatic diseases that may affect metabolic and/or intestinal function (e.g. diabetes, hypertension, dyslipidemia, irritable bowel disorder (ibd), gluten intolerance, pancreatic dysfunction, other causes of malabsorption, neoplastic disease) * allergies with previous anaphylactic reactions * abdominal surgery six months prior to inclusion * current or history of eating disorders * extreme or unusual diets for the last three months, which the investigator considers could negatively affect the outcome of the study * psychiatric disorders (e.g., schizophrenia, and other diagnoses that may influence compliance) * drug or alcohol abuse * continuous oral pharmacological treatment and other types of pharmacological treatment that may influence the study * present or recent usage of other probiotic agents * other conditions which the investigator considers could negatively affect the outcome of the study or study compliance
alcoholic hepatitis: a multicenter, observational study by the treat consortium

Conditions: Alcoholic Hepatitis

Summary: to conduct a prospective, multicenter, observational study of patients with well-characterized alcoholic hepatitis (ah) and frequency matched individuals (by age, gender, and race) with comparable history of alcohol consumption but no clinical evidence of liver disease (controls). at the end of the study, a robust clinical information, central bio-repository will be developed from both cases and controls.


Eligibility criteria:
cases: heavy drinkers with alcoholic hepatitis inclusion criteria 1. the diagnosis of ah will be established on published criteria this is based on: 1. average daily ethanol consumption of \> 40 grams/day for women and \> 60 grams/day for men for a minimum of 6 months and within the 6 weeks prior to study enrolment. judgment regarding daily and yearly alcohol use will be made by the site investigator 2. clinical evaluation and appropriate laboratory testing as defined by total bilirubin \> 2 mg/dl and ast \> 50 u/l. when the diagnosis of ah remains in question, a liver biopsy (if clinically feasible and that subject has no contra-indications) will be required. 3. subjects with hbv, hcv and/or hiv will be eligible for enrollment exclusion criteria 1. evidence of other liver diseases such as autoimmune or drug-induced 2. significant concomitant medical illnesses such as uncontrolled congestive heart failure or copd, or multiorgan failure 3. abstinence of alcohol use \> 6 weeks immediately preceding enrollment 4. hemochromatosis 5. wilson disease 6. active intravenous drug use controls: heavy drinkers without alcoholic hepatitis inclusion criteria 1. average daily ethanol consumption of \> 40 grams /day for women and \> 60 grams/day for males for a minimum of 6 months and within the 6 weeks prior to study enrollment. in addition, heavy drinkers who have just become abstinent within prior 2 weeks are eligible to be enrolled. judgment regarding daily and yearly alcohol use will be made by the site investigator 2. ast and alt ≤ 50 and total bilirubin levels within normal range. if bilirubin is increased due to a suspected gilbert's syndrome, patient may be enrolled if the direct bilirubin is within normal limits exclusion criteria 1. evidence of liver disease 2. significant concomitant medical illnesses such as uncontrolled congestive heart failure or copd, or multiorgan failure 3. abstinence of alcohol use \> 2 weeks immediately preceding enrollment 4. hemochromatosis 5. wilson disease 6. active intravenous drug use 7. prior history of known alcoholic liver disease 8. presence of hepatosplenomegaly from the physical examination/radiographic imaging or stigmata of liver disease
a prospective clinical study of the cloudcath system during in-home peritoneal dialysis

Conditions: Peritoneal Dialysis-associated Peritonitis

Summary: this study aims to determine if the cloudcath device can detect infections related to peritoneal dialysis (peritonitis) as fast or faster than the current standard methods used by patients and doctors to detect such infections.

this study will evaluate the safety and effectiveness of the cloudcath system to detect the onset of peritonitis as compared to standard of care. study participants will connect the cloudcath system to their home peritoneal dialysis unit and the cloudcath system will analyze the effluent dialysis solution for changes associated with peritonitis. the notification capability of the cloudcath system will be deactivated for this study so that neither study participants nor study investigators will be aware of the device measurements. following enrollment, study participants will use the cloudcath system for 12 continuous months.

Eligibility criteria:
key inclusion criteria: * currently using peritoneal dialysis * provides informed consent * willing to comply with the requirements of the study * has cellular data coverage at home key exclusion criteria: * active or history of cancer requiring chemotherapy within prior 6 months * signs or symptoms of an active infection within 14 days prior to enrollment * peritonitis diagnosis within 30 days prior to enrollment * participating in another investigational device or drug study that may potentially affect study results * other medical, social or psychological problems that, in the opinion of the investigator, exclude the study participant from the study
muscle architecture of lower extremity in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the aim of this study was to determine the muscle architecture of the lower extremity muscles (pennation angle, muscle fiber length and muscle thickness) in patients with multiple sclerosis. lower extremity muscles of patients with multiple sclerosis and healthy individuals; rectus femoris, biceps femoris, tibialis anterior, gastrosoleus and gastrocnemius muscles will be examined by ultrasound method.

multiple sclerosis (ms) is characterised by complex and heterogeneous symptoms, often leading to reduced quality of life and impaired functional capacity. the latter is related to reduced muscle strength of predominately the lower limbs . the mechanisms underlying the observed strength deficits are of muscular as well as neural origin . at the whole muscle level, a number of studies have examined skeletal muscle characteristics of ms patients, with some studies but not all, reporting loss of muscle mass and decreased or comparable maximal muscle strength. however, there is no study describing the features of lower extremity muscle architecture in multiple sclerosis. muscle architecture is defined as the alignment of muscle fibers with respect to the axis of force. although the diameters of the muscles of different sizes are quite similar to the diameters of the fibers, the sequences of these fibers contain several differences. the alignment of the muscle forming fibers has a significant effect on the force of muscle formation. the parameters that determine muscle architecture characteristics are the muscle fiber length, pennation angle, the physiological cross-sectional area. for each muscle these parameters may differ from each other. any type of load in the case is the result of an adaptation process that results in muscle development. muscle architecture allows the macroscopic understanding and interpretation of this adaptation process. determining the muscle architecture of multiple sclerosis patients by ultrasound will guide the rehabilitation process.

Eligibility criteria:
inclusion criteria: * 18-50 years old * individuals who agree to be voluntary, * with the edss 4 and below * without pregnancy * do not receive corticosteroid treatment in the last month * do not take any medicine that will affect walking in the last 1 month exclusion criteria: * those who refuse to volunteer, * edss over 4 * pregnancy * corticosteroid therapy within 1 month * any medication that will affect walking in the last 1 month

Keywords: multiple sclerosis muscle architecture lower extremity
effect of blueberries on cognition and body composition in elderly with mild cognitive decline

Conditions: Mild Cognitive Decline

Summary: purpose: the purpose of this study is to examine the effect of blueberry consumption on cognitive decline and body composition in humans. hypothesis 1: adults with mild cognitive decline who consume blueberries will experience an improvement in cognitive abilities as measured by a standardized battery of tests, relative to those who consume a placebo. hypothesis 2: adults with mild cognitive decline who consume blueberries will evidence an increase in processing speed and an improvement in memory abilities as measured in an electrophysiological paradigm and compared to those who consume a placebo. hypothesis 3: daily intake of 35 g freeze-dried blueberries will improve body composition (fat mass vs. lean mass). hypothesis 4: daily intake of 35 g freeze-dried blueberries will decrease oxidative stress and inflammatory markers.


Eligibility criteria:
inclusion criteria: * men and women age 65 and older * bmi between 18.5 and 34.5 * close individual to report memory decline exclusion criteria: * history of central nervous system or psychiatric disorders * dementia or alzheimer's diagnosis * diabetes * smoking \>20 cigarettes/day * gastrointestinal/digestive disorders * uncontrolled chronic disease
identification of genes predisposing to atherosclerosis

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases

Summary: to find genes important in the susceptibility to coronary heart disease.

background: coronary heart disease (chd) is a complex disorder constituting a major health problem in western societies. the study assesses the unknown genetic background of chd by investigating the most common familial dyslipidemia predisposing to chd, familial combined hyperlipidemia (fchl). the population prevalence of fchl is estimated to be 1-2 percent and the disorder affects 10-20 percent of families with premature chd. in fchl, serum cholesterol, triglycerides, or both are elevated. both environmental and genetic factors are suggested to affect the complex fchl phenotype. since the molecular basis of fchl is unknown, a significant number of genetically predisposed individuals remain unidentified and exposed to premature chd. the study uses samples from the genetically isolated population of finland. design narrative: the investigators will use the unique study samples from the genetically isolated population of finland and apply molecular genetic tools to first restrict the genetic locus they have identified and then to characterize the causative gene underlying the fchl disorder on chromosome 1q21. specifically, they first aim to further restrict the region by dissecting the different component traits. they will genotype an extended study sample consisting of all available family members of 61 fchl families with dense sets of microsatellite markers and single nucleotide polymorphisms to fully utilize the refined quantitative phenotype information in fine mapping. second, they aim to build a transcript map over the critical region on 1q21-q23 and to identify the causative fchl gene among the regional candidate genes. this region on 1q21-q23 is orthologous to a region on mouse chromosome 3, where a locus (hyplip 1) for combined hyperlipidemia has been identified. they have analyzed the human homolog of the hyplip 1 gene but disappointingly, the human hyplip 1 gene was found 10 mb from the peak linkage markers and no evidence emerged for hyplip 1 as a causative gene for fchl. their targets to identify the fchl gene are currently the genes showing strongest association near the linkage peak. the fchl gene will then be functionally characterized to prove the biological dysfunction. characterizing one gene for fchl would improve their understanding of molecular mechanisms of cardiovascular disease, and potentially lead to more accurate diagnosis, treatment and prevention.

Eligibility criteria:
no eligibility criteria
examining behavior therapy for trichotillomania in children and adolescents

Conditions: Trichotillomania

Summary: this study will evaluate a treatment for trichotillomania, or compulsive hair pulling, in children and adolescents.

trichotillomania (ttm) is a chronic impulse control disorder that causes people to pull out their own hair. ttm typically develops in late childhood or early adolescence. it has been suggested that, like with obsessive-compulsive disorder, early identification and treatment of ttm might prevent the disorder and other co-occurring disorders in adults. the researchers in this study have developed the first treatment for ttm to target children and adolescents. preliminary trials of this treatment, called behavior therapy (bt), indicate efficacy. this study is a larger, more rigorous examination of whether bt can successfully treat children and adolescents with ttm. participation in this study will be divided into two phases, each lasting 8 weeks. follow-up visits will occur 3 and 6 months after completing treatment. in phase 1, participants will be randomly assigned to receive either bt or supportive counseling (sc) for their ttm. both groups of participants will complete eight weekly study visits. those receiving bt will be encouraged to identify situations in which hair pulling is likely to occur and use behavioral techniques to resist urges to pull their hair. bt will also involve self-monitoring and homework throughout the week. those receiving sc will discuss ways to minimize interference of hair pulling with everyday life and receive education and emotional support from a study therapist-but will not be taught specific behavioral techniques. after 8 weeks, participants will be evaluated to determine whether treatment is helping them. if participants are receiving bt and showing reduction in symptoms, they will continue to phase 2, which involves four maintenance sessions of bt over 8 weeks. if participants receiving bt are not responding to treatment, they will be given referrals to other services. participants receiving sc will end their participation after 8 weeks, and those not responding to treatment will be offered bt. study assessments will be completed at baseline, after phase 1, after phase 2, and at 3- and 6-month follow-ups. these assessments will include a clinical interview, questionnaires about symptoms, and family assessment measures.

Eligibility criteria:
inclusion criteria: * diagnosis or symptoms of trichotillomania * presence of stable parent or guardian exclusion criteria: * presence of another primary or co-primary psychiatric disorder that requires initiation of different active current treatment * current use of psychotropic medication (participants may be able to stop taking medications to start with study)

Keywords: behavior therapy supportive counseling child adolescent hair pulling cbt
spy ii clinical registry

Conditions: Biliary Tract Diseases

Summary: a prospective, multi-center registry for subjects undergoing endoscopic retrograde cholangiopancreatography (ercp) and cholangioscopy for known or suspected pancreaticobiliary disease.


Eligibility criteria:
inclusion criteria: * male or female \>= 18 years of age * willing and able to comply with the registry procedures and provide written informed consent to participate in the registry * indicated for ercp or ercp/cholangioscopy (with or without biopsy) exclusion criteria: * subjects for whom endoscopic procedure are medically contraindicated * subjects for whom ercp are medically contraindicated * subjects for whom medical condition warrants use of device outside of indication for use

Keywords: biliary ercp cholangioscopy pancreatic
aura 1: augmenting urinary reflex activity: study 1

Conditions: Overactive Bladder; Urge Incontinence

Summary: aura 1 (augmenting urinary reflex activity: study 1) is a study that evaluates the electrophysiological responses of pudendal nerve stimulation using short-duration extracorporeal stimulation


Eligibility criteria:
inclusion criteria: * female patients aged ≥ 18 years with urological indications (oab, uui, ufs, retention syndromes and pain) * meeting criteria for routine snm (primary or revision surgery) at the discretion of their normal care urologist. * ability and willingness to give informed consent * willingness to stay overnight in hospital after snm procedure (as per routine care) exclusion criteria: * patient is pregnant, breastfeeding, or plans to become pregnant during the course of the study (pregnancy tests provided in schedule) \[this is an exclusion for snm in any case\] * any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints * any psychiatric or personality disorder at the discretion of the study physician * any neurological condition that may interfere with normal bladder function (e.g., stroke, multiple sclerosis, parkinson's disease; clinically significant peripheral neuropathy, or complete spinal cord injury) * patient has uncontrolled type i or type ii diabetes as defined by their routine care clinician or diabetes with peripheral nerve involvement * patient has history of other non-pelvic neoplasia within 5 years prior to enrolment, except for a cancer that was determined to be local occurrence only, such as basal cell carcinoma, or is receiving or planning to receive anti-cancer or anti-angiogenic drugs * patient has proven major autoimmune disease, e.g. scleroderma or immunodeficiency (including use of biologic immunomodulatory drugs at time of procedure) * patient is not suitable for the study as determined by their routine care physician for any other reason * patient is enrolled in another interventional study excepting observational studies, e.g. snm registries or in relation to disease (see below) * patient participation in vigorous sporting activities where these cannot be restricted for a period of 24h while the extracorporeal lead is in situ. specific urological • as per routine clinical snm criteria (see: https://www.nice.org.uk/guidance/ipg6434) specific technical * patient is significantly obese (defined as bmi ≥ 35) so as to limit electrode lead placement using standard approaches * skin, orthopaedic or neurological anatomical limitations that could prevent successful placement of the electrode lead * subject with a documented history of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
non-invasive measurement of co in patients with uncomplicated sepsis

Conditions: Sepsis

Summary: little is known about the optimal fluid therapy of patients with uncomplicated sepsis. most recommendations are extrapolated from studies performed in patients with septic shock. therefore, it is unknown how effective our current fluid therapy is. furthermore, current therapy is not tailored to individual needs. the aim of the current study is to investigate the added value of non-invasive measurements of (dynamic) circulatory parameters in the treatment of a convenience sample of sepsis patients presenting to the ed.


Eligibility criteria:
inclusion criteria: at presentation in the ed: * there has to be evidence of an infection: -temp \ 38 without an obvious cause for hypo-or hyperthermia * there has to be evidence of organ dysfunction by the presence of at least one of the following criteria: altered mental state, hypoxia (spo2\ 2 mmol/l in abga or vbga directly drawn after presentation, hypotension (map\ 22/min. exclusion criteria: * age\<16 * patients with septic shock (i.e. who remained hypotensive after fluid bolus administration, needing vasopressor therapy to obtain a map\>65 in the presence of a lactate \>2. (i.e. septic shock) these will be excluded afterwards, but will be shown in an inclusion flowchart. * subjects for whom it is impossible to obtain a reliable signal for clearsight measurements. * increased abdominal pressures * need for immediate ventilatory support or surgery * presence of an acute cerebral event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, active gastrointestinal bleed, trauma * known metastatic cancer * pregnancy

Keywords: passive leg raise fluid responsiveness cardiac output, non-invasive emergency department